Clinical trials: MGD-Meibomian Gland Dysfunction
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
- Trial name
- NCT03956225
- Testing
- Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
- Where
- 15 sites in United States
- Volunteers
- 299 people
- Sponsor
- Alcon Research
Meibomian Gland Dysfunction
Evaluation of the LipiFlow System With a New Activator
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject.
- Trial name
- NCT04500821
- Testing
- Activator LFD-2100
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics
Dry Eye, Dry Eye Syndromes
Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction
This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland…
- Trial name
- CLN-0154 (NCT07415330)
- Testing
- Lacrima VR System
- Volunteers
- 20 people
- Sponsor
- Demaod Ltd
Dry Eye, Meibomian Gland Dysfunction (Disorder)
Effect of a Dietary Supplement on Gut Microbiota and Ocular Surface Outcomes in Dry Eye Disease
This prospective clinical study investigates whether a dietary supplement product can modulate the gut microbiota and improve ocular surface outcomes in patients with dry eye disease.
- Conditions
- Dry Eye, Meibomian Gland Dysfunction (Disorder), Dry Eye Disease (DED), Dry Eye Disease, Meibomian Gland Disease
- Trial name
- NCT07148271
- Testing
- Dietary Supplement Product
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Varol TUNALI
Dry Eye, Meibomian Gland Dysfunction
Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
- Trial name
- NCT04795752
- Testing
- TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- Where
- 14 sites in United States
- Volunteers
- 345 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye, Meibomian Gland Dysfunction
IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03265652
- Testing
- Intense Pulsed Light (IPL) therapy
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Lumenis Be Ltd.
Improvement of Dry Eye Disease
Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction
The aim of the study is to evaluate the safety and efficacy of radiofrequency treatment for dry eye disease due to meibomian gland dysfunction
- Trial name
- NCT04120584
- Testing
- Forma Eye Applicator
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- InMode MD Ltd.
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
- Trial name
- Rhea (NCT06054217)
- Testing
- Vehicle of TP-03
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Meibomian Gland Dysfunction, Dry Eye Syndromes
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
- Trial name
- NCT05162261
- Testing
- Tixel C, LipiFlow
- Where
- 5 sites in United States
- Volunteers
- 109 people
- Sponsor
- Novoxel Ltd.
Meibomian Glands
Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD.
- Trial name
- NCT01979887
- Testing
- Meibum Expression
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Allergan
Dry Eye, Sjogren's Syndrome
Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye
The study aims to test the safety of Repetitive Magnetic Stimulation (RMS) treatment for dry eye disease. Patients are asked to undergo a one-time treatment with Epitech Ocular Magnetic Stimulation Device on one eye in the first…
- Conditions
- Dry Eye, Sjogren's Syndrome, Aqueous Tear Deficiency, Meibomian Gland Dysfunction
- Trial name
- NCT03012698
- Testing
- Ocular Repetitive Magnetic Stimulation (RMS) treatment
- Where
- 3 sites in Israel
- Volunteers
- 29 people
- Sponsor
- Epitech Mag Ltd.
Dry Eye, Evaporative Dry Eye Disease
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction
Dry eye disease (DED) is a common chronic condition characterized by ocular surface discomfort and tear film instability. Evaporative DED associated with meibomian gland dysfunction (MGD) is a frequent phenotype and is often…
- Conditions
- Dry Eye, Evaporative Dry Eye Disease, Meibomian Gland Dysfunction (Disorder)
- Trial name
- NCT07453212
- Testing
- Dietary Supplement: Microbiome-targeted oral supplement
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Varol TUNALI
Chalazion, Dry Eye Syndromes
Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
The objective of this study is to evaluate the clinical utility, safety and effectiveness of the Manual Mini System compared to standardized warm compress therapy for application of controlled, localized heat therapy in adult…
- Trial name
- NCT00832130
- Testing
- Manual Mini System, iHeat Portable Warm Compress Therapy
- Where
- 11 sites in United States
- Volunteers
- 139 people
- Sponsor
- TearScience, Inc.